Evidence map›Paper›PMID 40301553›Full record

ArticleProstate cancer and prostatic diseases2026

Gleason pattern 4 and active surveillance in patients with grade group 2 prostate cancer.

Alessandro Uleri, Michael Baboudjian, Riccardo Leni, Marco Oderda, Arthur Peyrottes, Claudia Kesch, Mulham Al-Nader, Charles Dariane, Helene Baud, Jonathan Olivier and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alessandro UleriDepartment of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France.ORCID http://orcid.org/0000-0002-2392-2775
Michael BaboudjianDepartment of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France. Michael.BABOUDJIAN@outlook.fr.ORCID http://orcid.org/0000-0001-6935-3873
Riccardo LeniDivision of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marco OderdaDivision of Urology, Department of Surgical Sciences, Molinette Hospital, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0003-4681-888X
Arthur PeyrottesDepartment of Urology and Renal transplantation, Université de Paris, APHP, Saint Louis Hospital, Paris, France.
Claudia KeschDepartment of Urology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.ORCID http://orcid.org/0000-0002-2656-2664
Mulham Al-NaderDepartment of Urology, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany.
Charles DarianeDepartment of Urology, Hôpital Européen Georges-Pompidou, Université Paris Cité, Paris, France.
Helene BaudDepartment of Urology, Hôpital Européen Georges-Pompidou, Université Paris Cité, Paris, France.
Jonathan OlivierUrology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
Anna Redondo RiosDepartment of Urology, Fundació Pugivert, Barcelona, Spain.
Francesco SanguedolceDepartment of Urology, Fundació Pugivert, Barcelona, Spain.
Vincent BenardDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Olivier WindischDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.ORCID http://orcid.org/0000-0002-8963-5445
Massimo ValerioDivision of Urology, Geneva University Hospitals, Geneva, Switzerland.
Giorgio GandagliaDivision of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Guillaume PloussardDepartment of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.ORCID http://orcid.org/0000-0002-6004-2152

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo report active surveillance (AS) outcomes in patients with Grade Group (GG) 2 prostate cancer (PCa) according to the baseline amount of pattern 4 on image-guided biopsy.

methodsOur database includes GG2 PCa patients managed with AS in ten European centers.

resultsIn total, 104 patients were included (median pattern 4: 10%, ranges 5-40). The percentage of pattern 4 was not statistically correlated with upgrading (Spearman, r = 0.073, p = 0.5) or downgrading on confirmatory biopsy (r = -0.049, p = 0.6). The median follow-up was 33 months. In multivariable Cox regression analysis, percentage of pattern 4 was not associated with GG3 upgrading (p = 0.6) or definitive treatment (p = 0.4).

conclusionsPatients with GG2 PCa should not be excluded from AS solely because of grade 4 > 10% when other parameters are otherwise favorable.

Indexed as

Prostatic NeoplasmsWatchful WaitingAgedAged, 80 and overFollow-Up StudiesHumansImage-Guided BiopsyMaleMiddle AgedNeoplasm GradingPrognosisProstateProstate-Specific AntigenRetrospective StudiesProstate-Specific Antigen

Identifiers

PMID40301553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.